Radiopharm Theranostics

September Quarterly Report: https://buff.ly/3UqL4gq - First patient dosed in Phase 1 therapeutic RAD204 Non-Small Cell Lung Cancer trial - FDA IND approval received for RAD101 Phase 2b brain metastases trial - Dr Dimitris Voliotis appointed as Chief Medical Officer - Increase in ownership of Radiopharm Ventures to 75% - ADR program launched for US investors

New imaging data presented at EANM 2024 for Ga68-RAD 202 has confirmed rapid tumor uptake, favorable biodistribution and low uptake in non-specific organs: https://buff.ly/3NDglc4 The comprehensive preclinical data package demonstrates tumor growth inhibition and significantly prolonged survival time, supporting readiness for the Phase I therapeutic trial with 177Lu-RAD 202.

RAD and BAMF Health have announced a strategic collaboration to manufacture and dose 18F-RAD 101 for the Phase 2b imaging study of brain metastasis: https://buff.ly/4hemyJ9 Enrolment is anticipated to commence in Q4 2024.

Our Managing Director Riccardo Canevari spoke to Brookline Capital Markets analyst Kemp Dolliver this week. Read the report from their fireside chat on RAD: https://buff.ly/40a1qh5

RAD and AtomVie Global Radiopharma Inc. have partnered to develop and manufacture 177Lu-BetaBart, a 177Lutetium-conjugated B7-H3 targeting radioantibody. This partnership leverages both companies' expertise to advance novel radiotherapeutic solutions in areas of high unmet medical needs: https://buff.ly/3YaHpod

Tony Locantro highlighted RAD on Stockhead TV this week, discussing the recent investment from Lantheus as well as the Company’s current pipeline. Click here to view the segment (starts at 1:40): https://buff.ly/3XYxP7A

Tony Locantro highlighted RAD on Stockhead TV this week, discussing the recent investment from Lantheus as well as the Company’s current pipeline. Click here to view the segment (starts at 1:40): https://buff.ly/3XYxP7A

RAD has made significant progress on its B7-H3 targeting radio-antibody, BetaBart. A pre-IND meeting request with the #FDA has been submitted, and the first GMP batch of the antibody and chelator was successfully produced: https://buff.ly/3YaFZv7 The Phase I/II clinical trial is expected to begin in mid-2025.

RAD has been invited to present at the JonesResearch Virtual Radiopharma Day, which is taking place later this month: https://lnkd.in/gqWBws9a It will feature fireside chats and panel discussions with public and private companies in the sector, as well as accommodating 1-on-1 meetings with investors.

RAD is pleased to announce the appointment of Noel Donnelly as a Non-Executive Director: https://buff.ly/4erjdoa Mr Donnelly brings over 25 years of leadership experience in finance, strategy, and operations within the biopharmaceutical and biotechnology industries. He has a distinguished track record of building and leading cross-functional teams, driving corporate governance, and executing complex financial strategies that support rapid company growth. #biotech #medtech